| Literature DB >> 28251049 |
Zhe Wang1, Huiyu Liu2, Sijin Liu3.
Abstract
Breast cancer is the fifth most common cause of cancer death in the world and the second most common fatal cancer in women. Epidemiological studies and clinical data have indicated that hormones, including estrogen, progesterone, and prolactin, play important roles in the initiation and progression of breast cancer. Bisphenol A (BPA) is one of the most commonly used and thoroughly studied endocrine disruptors. It can be released from consumer products and deposited in the environment, thus creating potential for human exposure through oral, inhaled, and dermal routes. Some recent reviews have summarized the known mechanisms of endocrine disruptions by BPA in human diseases, including obesity, reproductive disorders, and birth defects. However, large knowledge gaps still exist on the roles BPA may play in cancer initiation and development. Evidence from animal and in vitro studies has suggested an association between increased incidence of breast cancer and BPA exposure at doses below the safe reference doses that are the most environmentally relevant. Most current studies have paid little attention to the cancer-promoting properties of BPA at low doses. In this review, recent findings on the carcinogenic effects of low-dose BPA on breast cancer and discussed possible biologic mechanisms are summarized.Entities:
Keywords: bisphenol A; breast cancer; carcinogenesis; low doses
Year: 2016 PMID: 28251049 PMCID: PMC5323866 DOI: 10.1002/advs.201600248
Source DB: PubMed Journal: Adv Sci (Weinh) ISSN: 2198-3844 Impact factor: 16.806
Figure 1Chemical structures of BPA, DES, and estradiol. The structure of BPA is more similar to DES than it is to endogenous estradiol.
Carcinogenic effects induced by BPA on different organs
| Carcinogenic organ | Animal species | Exposure Doses | Observed effects | Ref. |
|---|---|---|---|---|
| Mammary | Mouse | 0.6 µg–1.2 mg kg–1 day–1 | Perinatal exposure to BPA increased the number of TEBs and progesterone response mammary epithelial cells |
|
| Rat | 0.25–1,000 µg kg–1 day–1 | Perinatal exposure to BPA induced ductal hyperplasias, ductal carcinoma in situ and malignant tumors |
| |
| Nonhuman primates | 400 µg kg–1 day–1 | Fetal exposure to BPA increased the density of mammary buds and accelerated mammary epithelial development |
| |
| Ovary | Mouse | 0.1–1,000 µg kg–1 day–1 | Prenatal exposure to BPA induced ovarian cysts and cystadenomas and increased progressive proliferative lesions of the oviduct |
|
| Rat | 5–500 µg kg–1 day–1 | Neonatal exposure to BPA led to polycystic ovarian syndrome |
| |
| Uterus | Mouse | 10–1,000 µg kg–1 day–1 | Neonatal exposure to BPA increased the incidence of cystic endometrial hyperplasia, adenomyosis and leiomyomas |
|
| Prostate | Mouse | 100–250 µg kg–1 day–1 | BPA exposure increased the incidence of prostate intraepithelial neoplasia and adenocarcinoma of human progenitor cells in renal xenograft model |
|
| Rat | 10 µg kg–1 day–1 | Neonatal exposure to BPA increased the incidence of prostatic intraepithelial neoplasms |
| |
| Testes | Rat | 2.5–25 µg kg–1 day–1 | Perinatal exposure to BPA stimulated Leydig cell proliferation and increased Leydig cell number |
|
| Liver | Mouse | 0.5 ng–50 mg kg–1 day–1 | Perinatal exposure to BPA induced hepatic preneoplastic and neoplastic lesions |
|
Figure 2Schematic representation of mammary gland development at distinct stages under the control of hormones.
Sources of contamination, estimated concentrations and exposure routes of BPA in environment and daily life
| Contamination sources | BPA concentrations | Exposure routes | Ref. |
|---|---|---|---|
| Acquatic environment | Up to 56 µg L–1 | Ingestion |
|
| Soil | 1–150 µg kg–1 | Ingestion |
|
| Landfill leachates | Up to 17.2 mg L–1 | Ingestion |
|
| Air | 2–208 ng m–3 | Inhalation |
|
| Dust | 0.2–17.6 µg g–1 | Inhalation |
|
| Contaminated seafood | 13.3–213.1 µg kg–1 | Ingestion |
|
| Metal food cans | 2–82 ng g–1 | Ingestion |
|
| Plastic bottles | 0.234 µg L–1 | Ingestion |
|
| Thermal paper | 7.1–71 µg day–1 | Dermal route |
|
| Dental materials | 0.013–30 mg day–1 | Dermal route |
|
In Vivo and In Vitro Studies on Mammary Gland Carcinogenesis from Exposure to Low‐Dose BPA
| Experimental model | Exposure Doses | Exposure time | Observed effects | Ref. |
|---|---|---|---|---|
| Females | ||||
| CD‐1 mouse | 0.25 µg kg–1 day–1 | E8‐18 | Increased ductal area and extenion, inhibited lumen formation, altered extracellular matrix organization and enhanced fat pad mature |
|
| CD‐1 mouse | 0.025 and 0.25 µg kg–1 day–1 | E9‐PND4 | Increased number of lateral branching, the area of TEBs and progesterone expressing epithelial cells |
|
| C57BL/6 mouse | 0.6 µg–1.2 mg kg–1 day–1 | E1‐PND24 | Increased number of TEBs (0.6, 3, and 6 µg kg–1 day–1 only) |
|
| CD‐1 mouse | 0.25, 2.5, and 25 µg kg–1 day–1 | E8‐PND16 | Increase in intraductal hyperplasia formation |
|
| Wistar‐Furth rat | 2.5, 25, 250 and 1000 µg kg–1 day | E9‐PND1 | Increased number of hyperplastic ducts at PND90 (2.5 µg kg–1 day–1 only) |
|
| Sprage‐Dawley rat | 0.25, 2.5, 25 and 250 µg kg–1 day–1 | E9‐PND1 and E9‐PND21 | Increase in ductal hyperplasias and ductal carcinoma in situ, presence of palpable tumors |
|
| FVB/N mouse | 25, 250 µg kg–1 day–1 | E8‐ parturition | Decreased tumor latency and increased susceptibility to DMBA‐induced tumors in a dose‐dependent mannar |
|
| Sprage‐Dawley rat | 25, 250 µg kg–1 day–1 | PND2‐PND20 | Increased number of mammary tumors and susceptibility to DMBA‐induced tumors in a dose‐dependent mannar |
|
| Wistar rat | 25 µg kg–1 day–1 | E8‐23 | Increased number of hyperplastic ducts and developed NMU‐induced ductal carcinoma in situ |
|
| MMTV‐erbB2 | 2.5, 25, 250 and 2500 µg L–1 drinking water | 56‐252 days of age | Decreased tumor latency, increased tumor multiplicity, tumor volume and pulmonary metastasis (2.5 and 25 µg L–1 water only) |
|
| Males | ||||
| CD‐1 mouse | 0.25, 2.5, 25 and 250 µg kg–1 day–1 | E8‐PND16 | Increased number of branching points and enhanced epithelial proliferation in age‐ and dose‐dependent manners |
|
| In vitro cells | ||||
| MCF‐7 cells | 10–25 nM | 6 days | Increase in rate of cell proliferation and levels of progesterone receptors |
|
| T47D cells | 100 nM | 7 days | Decrease in cell apoptosis |
|
| Nonmalignant breast cells from breast cancer patients | 100 nM | 7 days | Changes in gene expression associated with high tumor grade, large tumor size and poor prognosis for patients |
|
| T47D and MDA‐MB‐468 cells | 1 nM | 24 h | Reduction in the efficacy of multiple chemotherapeutic agents |
|
Low dose for in vitro BPA effects was defined an equivalent low dose concentrations as ≤100 nM according to most experimental designs.
Figure 3Estrogenic activities of BPA. Xenoestrogen BPA can interact with nuclear estrogen receptors (ERs), cytoplasmic ERs, membrane‐bound ERs and GPR30 receptors, inducing mammary epithelial cell proliferation through genomic and non‐genomic signaling pathways.
Figure 4A schematic diagram showing the effects of BPA on the breast microenvironment. BPA promotes carcinogenesis of breast cancer by affecting the environment surrounding mammary epithelial cells, i.e., the breast microenvironment. BPA may adversely influence various cell types within the gland, such as fibroblasts, adipocytes, and immune cells, thus changing soluble factor secretion, extracellular matrix components and organization, and the local immune context. All of these alterations can lead to chronic inflammation, modification of tissue homeostasis, and neoplastic transformation of mammary epithelial cells.
Figure 5Schematic overview of possible pathways by which BPA promotes mammary carcinogenesis.